Pediatrics

Authors noted it may be worthwhile to explore whether oral methylphenidate affects myopia by influencing dopamine levels

A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children

Compared with penicillin, investigators reported no significant differences in the incidence of ophthalmologic manifestations among patients treated with ceftriaxone.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1,310 nm that can scan at a speed of 50,000 A-scan/second.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.

At ARVO 2025, in Salt Lake City, Utah, Noemi Guemes-Villahoz, MD, PhD, talked about 12-month results of vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

Chinese researchers reveal that low-level red light therapy may control myopia in children but raises concerns about retinal damage and cone density reduction.

ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.

This population requires careful attention from diagnosis through the entire postoperative process.

The affected mandate requires that all newborns receive erythromycin ointment applied to their eyes after birth, which helps prevent ophthalmia neonatorum.

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

Accelerated changes in the spherical equivalent refraction (SER) and axial length were seen but no changes in the lens power and thickness were seen in pediatric patients.

The study findings indicated that lifestyle changes associated with the COVID-19 pandemic were connected to an increase in childhood astigmatisms.

The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.